Curasight is a clinical stage biotech company committed to improving both diagnosis and the treatment of certain types of cancer. Utilizing its cutting-edge uPAR Theranostic radionuclide platform, the company is able to more accurately characterize the type and stage of the tumor using intelligent cancer imaging (uTRACE®) and with that knowledge, develop a more targeted, gentle, and efficient approach to treatment (uTREAT®). The company was founded on a strong understanding of nuclear medicines, based on 10 years of research at Copenhagen’s University hospital, Rigshospitalet. Led by science and industry experts, Curasight has built a pipeline of products which have been tested to Phase 2 of clinical development and which are robustly patent protected. Located in Copenhagen, Denmark, the company has strong international partnerships both in academia and industry and is firmly committed to using its pioneering technology to improve the lives of cancer patients globally.

Curasight

Curasight is built on more than a decade of research in PET imaging in cancer diseases at the University of Copenhagen and Rigshospitalet. Part of our company strategy is focused on the discovery and development of novel radiopharmaceuticals for improved diagnose, risk-stratification and treatment monitoring in cancer diseases using PET imaging. Our current PET ligand discovery research program and our academic collaborations are focused on discovering and developing disease-specific PET ligands for multiple cancer indications. Another part of our strategy is to develop partnerships with larger pharmaceutical or biotechnology firms that improve our ability to move new PET ligands through the late stage clinical trials and to bring them into the marketplace.

Seed Capital

PreSeed Ventures

The Curasight team is proud to be nominated in the EY Entrepreneur Of The Year 2023 in the Life Sciences category

#curasight #EY2023 #eyentrepreneuroftheyear #lifescience

Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

#Curasight #cancer #braincancer #uTRACE #uTREAT #uPARPET #theranostics

#Curasight #Cancer #uTRACE #uTREAT #braincancer #prostatecancer #uPAR

New positive results for Curasight in brain cancer

#curasight #braincancer #cancer #glioblastoma #utrace #utreat #theranostic #upar

Positive resultater i fase II studie i hjernekræft med uTRACE

#Curasight #cancer #braincancer #glioblastoma #uTREAT #uPAR

Positive studieresultater mod hjernekræft styrker investeringscasen i Curasight

Curasight A/S reports positive preclinical results with uTREAT® in aggressive brain cancer (glioblastoma)
 ·        Preclinical studies show uTREAT® effective in treating aggressive brain cancer
·        Data supports strategy to move uTREAT® into clinical development for evaluation in patients with aggressive brain cancer
#Curasight #cancer #braincancer #Glioblastoma #Glioma #data #uTREAT #uPAR

Curasight presents the Interim Report Q1 2023 at HC Andersen Capital

#Curasight #Cancer #InterimreportQ12023 #uTRACE #uTREAT #uPAR

COM:CURASIGHT

Curasight

Financials Not Available